ArticleParasites & vectors2025
Clonorchis sinensis-driven hepatocarcinogenesis via E2F1-CD24 transcriptional axis: mechanistic and therapeutic implications.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The metastasis landscape ofFrontiers in immunology · 2026Article
- Regulation of immune checkpoints by electronic cigarette.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) remains a global health burden, with disproportionately high mortality in China's Guangxi region, where endemic Clonorchis sinensis (C. sinensis) infection coincides with elevated HCC incidence. Preliminary single-cell sequencing revealed marked overexpression of cluster of differentiation 24 (CD24) in HCC tissues, suggesting its potential pathological role. This study aims to elucidate the oncogenic mechanisms of C. sinensis excretory-secretory products (CsESPs) and their link to CD24-mediated HCC progression.
methodsWe employed an integrated clinical and experimental approach. First, clinical cohort analysis assessed CD24 expression in C. sinensis-associated HCC cases. Multiplatform bioinformatics validation (GEPIA/UALCAN/TIMER) evaluated CD24's prognostic significance and immune microenvironment modulation. Functional studies (quantitative polymerase chain reaction (qPCR), Western blotting, CCK-8 assays, flow cytometry) examined CsESPs' effects on CD24 expression, cell proliferation, and apoptosis. Mechanistic investigations (chromatin immunoprecipitation, dual-luciferase reporter assays) identified E2F1-mediated transcriptional activation of CD24. siRNA-mediated CD24 knockdown validated its role in CsESPs-driven oncogenesis. Additionally, the expression of immune checkpoint (CTLA-4, LAG-3) was assessed in the co-cultures of peripheral blood mononuclear cells (PBMCs)-HCC cells.
resultsClinical cohort analysis confirmed significant CD24 upregulation in HCC, particularly in C. sinensis-infected cases. Bioinformatic analyses linked high CD24 expression to poor prognosis and immune microenvironment alterations. Functional assays demonstrated that CsESPs enhance CD24 expression, promoting proliferation and inhibiting apoptosis. Mechanistically, E2F1 directly binds to CD24 promoter, driving its transcription upon CsESPs exposure. CD24 silencing reversed CsESPs-induced oncogenic effects. Furthermore, CsESPs upregulated immune checkpoints (CTLA-4, LAG-3) in the co-cultures of PBMC-HCC cells, an effect reversed by CD24 knockdown.
conclusionsOur findings establish a novel parasitic carcinogenesis paradigm wherein C. sinensis promotes HCC development through E2F1-mediated transcriptional activation of CD24, simultaneously identifying prognostic biomarkers and therapeutic targets while suggesting combinatory immunotherapy strategies for parasite-associated HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.